• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:1型酪氨酸血症中的注意力缺陷多动障碍及预后

Case report: ADHD and prognosis in tyrosinemia type 1.

作者信息

Barone Helene, Elgen Irene Bircow, Bliksrud Yngve Thomas, Vangsøy Hansen Eirik, Skavhellen Rita Rigmor, Furevik Magne Ivar, Haavik Jan

机构信息

Regional Resource Center for Autism, ADHD and Tourette Syndrome, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.

Department of Child and Adolescent Psychiatry, Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.

出版信息

Front Psychiatry. 2023 Jul 18;14:1213590. doi: 10.3389/fpsyt.2023.1213590. eCollection 2023.

DOI:10.3389/fpsyt.2023.1213590
PMID:37533886
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10392124/
Abstract

Neurometabolic disorders such as tyrosinemia type 1 (TYRSN1) may interfere with brain metabolism and show symptoms of attention-deficit hyperactivity disorder (ADHD) in patients treated with the enzyme inhibitor nitisinone [2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, NTBC]. It has been reported that ADHD treatment improves treatment compliance, which is imperative for the long-term prognosis of patients with TYRSN1. In this study, we report the case of a male patient who was diagnosed with TYRSN1 at 3 months of age and was subsequently treated with NTBC, restricted protein intake, and amino acids supplementation. At 7 years of age, he was referred for neuropsychiatric assessment, diagnosed with ADHD, and treated with methylphenidate. The effects of the treatment were monitored via parental interviews, questionnaires covering ADHD symptoms, and a continuous performance test. A reduction in ADHD symptoms, particularly inattentiveness, was observed across all measures. The early identification of ADHD and the treatment of neurometabolic disorders, such as TYRSN1, may be important from a lifetime perspective as this may improve the prognosis of the medical condition as well.

摘要

诸如1型酪氨酸血症(TYRSN1)等神经代谢紊乱可能会干扰大脑代谢,并在接受酶抑制剂尼替西农[2-(2-硝基-4-三氟甲基苯甲酰基)-1,3-环己二酮,NTBC]治疗的患者中表现出注意力缺陷多动障碍(ADHD)的症状。据报道,ADHD治疗可提高治疗依从性,这对于TYRSN1患者的长期预后至关重要。在本研究中,我们报告了一名男性患者的病例,该患者在3个月大时被诊断为TYRSN1,随后接受了NTBC治疗、限制蛋白质摄入和补充氨基酸。7岁时,他因神经精神评估前来就诊,被诊断为ADHD,并接受了哌甲酯治疗。通过家长访谈、涵盖ADHD症状的问卷以及持续操作测试来监测治疗效果。在所有测量指标中均观察到ADHD症状有所减轻,尤其是注意力不集中的症状。从终身角度来看,早期识别ADHD以及治疗诸如TYRSN1等神经代谢紊乱可能很重要,因为这也可能改善病情的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc71/10392124/06db77c42d96/fpsyt-14-1213590-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc71/10392124/06db77c42d96/fpsyt-14-1213590-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc71/10392124/06db77c42d96/fpsyt-14-1213590-g0001.jpg

相似文献

1
Case report: ADHD and prognosis in tyrosinemia type 1.病例报告:1型酪氨酸血症中的注意力缺陷多动障碍及预后
Front Psychiatry. 2023 Jul 18;14:1213590. doi: 10.3389/fpsyt.2023.1213590. eCollection 2023.
2
The effects of phenylalanine and tyrosine levels on dopamine production in rat PC12 cells. Implications for treatment of phenylketonuria, tyrosinemia type 1 and comorbid neurodevelopmental disorders.苯丙氨酸和酪氨酸水平对大鼠 PC12 细胞中多巴胺生成的影响。对苯丙酮尿症、酪氨酸血症 1 型和共病神经发育障碍治疗的启示。
Neurochem Int. 2023 Dec;171:105629. doi: 10.1016/j.neuint.2023.105629. Epub 2023 Oct 20.
3
Outcome of Tyrosinemia Type 1 in Indian Children.印度儿童1型酪氨酸血症的结局
J Clin Exp Hepatol. 2021 Jan-Feb;11(1):9-13. doi: 10.1016/j.jceh.2020.07.002. Epub 2020 Jul 11.
4
Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report.1型酪氨酸血症的诊断及早期治疗的重要性:一例病例报告。
Clin Mass Spectrom. 2019 Feb 2;12:1-6. doi: 10.1016/j.clinms.2019.01.005. eCollection 2019 Apr.
5
Case report: Maternal tyrosinemia type 1a under NTBC treatment with tyrosine- and phenylalanine restricted diet in Chile.病例报告:智利 NTBC 治疗下的 1a 型母系酪氨酸血症,限制饮食中的酪氨酸和苯丙氨酸。
Am J Med Genet C Semin Med Genet. 2020 Dec;184(4):1009-1013. doi: 10.1002/ajmg.c.31863. Epub 2020 Dec 10.
6
Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).遗传性I型酪氨酸血症诱导的肝脏基因表达的广泛变化不能通过用2-(2-硝基-4-三氟甲基苯甲酰基)-1,3-环己二酮(NTBC)治疗而恢复正常。
J Hepatol. 2003 Dec;39(6):901-9. doi: 10.1016/s0168-8278(03)00433-1.
7
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.速释型哌甲酯用于治疗成人注意力缺陷多动障碍(ADHD)
Cochrane Database Syst Rev. 2014 Sep 18(9):CD005041. doi: 10.1002/14651858.CD005041.pub2.
8
Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.尽管使用了尼替西农治疗且甲胎蛋白恢复正常,但1型遗传性酪氨酸血症仍需肝移植的肝细胞癌。
Pediatr Transplant. 2022 Nov;26(7):e14334. doi: 10.1111/petr.14334. Epub 2022 Jun 13.
9
Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.成人注意缺陷多动障碍(ADHD)评估和管理的实用考虑因素。
Encephale. 2020 Feb;46(1):30-40. doi: 10.1016/j.encep.2019.06.005. Epub 2019 Oct 11.
10
Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia.酪氨酸血症停用尼替西农(NTBC)治疗后的神经危机
Iran J Child Neurol. 2017 Fall;11(4):66-70.

引用本文的文献

1
Variations in salivary microbiota and metabolic phenotype related to oral lichen planus with psychiatric symptoms.与伴有精神症状的口腔扁平苔藓相关的唾液微生物群和代谢表型的变化。
BMC Oral Health. 2025 Jul 2;25(1):993. doi: 10.1186/s12903-025-06439-8.
2
The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models.注意缺陷多动障碍的多巴胺假说:对来自人体研究和动物模型的证据评估
Front Psychiatry. 2024 Nov 15;15:1492126. doi: 10.3389/fpsyt.2024.1492126. eCollection 2024.
3
Effects of a Tailored Pediatric Rehabilitation Protocol on Children With Neurometabolic Disorder: A Case Report.

本文引用的文献

1
Genome Guided Personalized Drug Therapy in Attention Deficit Hyperactivity Disorder.注意缺陷多动障碍中的基因组导向个性化药物治疗
Front Psychiatry. 2022 Jun 27;13:925442. doi: 10.3389/fpsyt.2022.925442. eCollection 2022.
2
ADHD symptoms in neurometabolic diseases: Underlying mechanisms and clinical implications.神经代谢性疾病中的注意缺陷多动障碍症状:潜在机制与临床意义。
Neurosci Biobehav Rev. 2022 Jan;132:838-856. doi: 10.1016/j.neubiorev.2021.11.012. Epub 2021 Nov 11.
3
Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study.
个性化儿科康复方案对神经代谢障碍患儿的影响:病例报告
Cureus. 2024 Mar 28;16(3):e57115. doi: 10.7759/cureus.57115. eCollection 2024 Mar.
在瑞典进行的一项基于遗传信息的登记研究:成年 ADHD 与身体状况之间的表型和病因关联的研究。
Lancet Psychiatry. 2021 Sep;8(9):774-783. doi: 10.1016/S2215-0366(21)00171-1. Epub 2021 Jul 6.
4
ADHD should be considered in adolescents with type 1 diabetes and poor metabolic control.1型糖尿病且代谢控制不佳的青少年应考虑患有注意力缺陷多动障碍(ADHD)。
Diabetologia. 2021 Aug;64(8):1897-1898. doi: 10.1007/s00125-021-05493-5. Epub 2021 Jun 9.
5
Treatment adherence in tyrosinemia type 1 patients.1 型酪氨酸血症患者的治疗依从性。
Orphanet J Rare Dis. 2021 Jun 3;16(1):256. doi: 10.1186/s13023-021-01879-1.
6
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.1 型酪氨酸血症的药物治疗的长期结果和实际考虑
Paediatr Drugs. 2019 Dec;21(6):413-426. doi: 10.1007/s40272-019-00364-4.
7
Tyrosinemia Type 1 and symptoms of ADHD: Biochemical mechanisms and implications for treatment and prognosis.I 型酪氨酸血症与 ADHD 症状:生化机制及其对治疗和预后的影响。
Am J Med Genet B Neuropsychiatr Genet. 2020 Mar;183(2):95-105. doi: 10.1002/ajmg.b.32764. Epub 2019 Oct 21.
8
Previously undiagnosed attention-deficit/hyperactivity disorder associated with poor metabolic control in adolescents with type 1 diabetes.先前未被诊断出的注意力缺陷/多动障碍与 1 型糖尿病青少年代谢控制不良有关。
Pediatr Diabetes. 2018 Jun;19(4):816-822. doi: 10.1111/pedi.12651. Epub 2018 Mar 24.
9
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.I 型酪氨酸血症的诊断和治疗:美国和加拿大共识小组的回顾和建议。
Genet Med. 2017 Dec;19(12). doi: 10.1038/gim.2017.101. Epub 2017 Aug 3.
10
Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients.I型酪氨酸血症患者的神经和神经心理问题
Adv Exp Med Biol. 2017;959:111-122. doi: 10.1007/978-3-319-55780-9_10.